Hikma Pharmaceuticals PLC: Business Overview, Financials & Competitive Analysis
Hikma Pharmaceuticals PLC scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified generics and specialty pharma company with strong MENA/North America exposure, solid margins, and disciplined M&A strategy positioned for steady growth. Hikma is actively launching new products, signing partnerships, investing in R&D, building new manufacturing plants, and deploying capital through acquisitions. The company generates majority revenue from its generics.
What is Hikma Pharmaceuticals PLC's industry? Hikma Pharmaceuticals PLC (hikma.com) operates in Pharmaceuticals - Generics & Specialty. AskCyborg classifies Hikma Pharmaceuticals PLC under Pharmaceuticals - Generics & Specialty in its company registry.
Hikma Pharmaceuticals specializes in developing, producing, and selling drugs for treating cardiovascular diseases, infections, cancers, diabetes, and other conditions. With TTM revenue of $3.12 billion as of January ...
Cyborg Score thesis
Diversified generics and specialty pharma company with strong MENA/North America exposure, solid margins, and disciplined M&A...
Read the full analyst-debate transcript →Get the Latest Hikma Pharmaceuticals PLC Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHikma Pharmaceuticals PLC Overview
Pro stress-test →Hikma Pharmaceuticals specializes in developing, producing, and selling drugs for treating cardiovascular diseases, infections, cancers, diabetes, and other conditions. With TTM revenue of $3.12 billion as of January 2026, the company demonstrates consistent growth with 2024 revenue increasing from $2.87 billion in 2023.
Strategic Profile
Pro stress-test →The company operates across three segments: Branded Pharmaceuticals, Generic Pharmaceuticals, and Injectable Pharmaceuticals. Revenue is driven primarily by generic injectable products (41.8%), oral generics (32.8%), and branded drugs (24.68%), with North America accounting for 61.1% of sales and Middle East/North Africa representing 31.5%.
Competitive Landscape
Pro stress-test →Hikma competes against 30+ pharmaceutical companies including Lupin. The company differentiates through scale in generics, injectables manufacturing footprint, and geographic diversification, particularly in MENA and North America where it has established market presence versus larger global peers.
Industry Context
Hikma Pharmaceuticals PLC operates in Pharmaceuticals - Generics & Specialty.
Key facts
Founded: 1978 · Headquarters: London, UK · Employees: 9,500 · Revenue: $3.12B · Market cap: $3.49B